Assessment the prevalence of high-risk human papillomavirus types 16 and 18 in 15 to 45 years old women
Archives of Medical Laboratory Sciences,
Vol. 2 No. 4 (2016),
16 April 2017
https://doi.org/10.22037/amls.v2i4.17054
Abstract
Background: Cervical cancer is the fourth most common cancer in incidence and the first genital cancer in women around the world, which 95% of them are related to human papillomavirus (HPV) infections. The risk of cervical cancer increases 10-12 time in women with HPV infection. This study aim to evaluate the prevalence of high-risk HPV infections among 15-45 years old women.
Materials and Methods: This cross sectional study was carried out on 92 normal women who admitted at Semnan hygiene center and has 15-45 years old. Cervical samples were collected using Cytobrush cell collector and consequently DNA extraction was performed using commercial DNA extraction kit. Polymerase Chain Reaction (PCR) was done using HPV (GP5, GP6) universal primers accompanied by positive and negative control in each PCR run. In order to extracted DNA template quality control, actin gene used as housekeeping gene.
Results: In this investigation, study subjects age range found to be 15-45 with mean of 30±0.9 years old. HPV infection was not found in patient group. Thus, further approach in order to HPV16 and HPV18 types detection, was not performed. However, other studies represented low to moderate prevalence for HPV in some regions of Iran.
Conclusion: Cervical cancer is one the major health concern and the fourth most common cancer around the world. This cancer is more common in developing countries than developed countries due to lack of screening program. Regard to possible high prevalence rate of HPV virus and its association with cervical cancer, we suggest further determination of the HPV prevalence as well as planning in large-scale vaccination in high risk group.
- Human Papilloma Virus
- Cervical cancer
- Prevalence
- HPV18
How to Cite
References
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). World HealthOrganization; 2012 (cited 2013). Available from: http://globocan.iarc.fr accessed on day/month/year.
Yousefzadeh A, Mostafavizadeh SM, Jarollahi A, Raeisi M, Garshasbi M, Siavashvahabi Z, et al. Human papillomavirus (HPV) prevalence and types among women attending regular gynecological visit in Tehran, Iran. Clinical laboratory. 2014;60(2):267-73.
Todd RW, Steele JC, Etherington I, Luesley DM. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia. Gynecologic oncology. 2004;92(1):167-74.
Parfenov M, Pedamallu CS, Gehlenborg N ,Freeman SS, Danilova L, Bristow CA, et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(43):15544-9.
Munger K, Phelps WC ,Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. Journal of virology. 1989;63(10):4417-21.
de Freitas AC, Coimbra EC, Leitao Mda C. Molecular targets of HPV oncoproteins: potential biomarkers for cervical carcinogenesis. Biochimica et biophysica acta. 2014;1845(2):91-103.
Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S, Desaintes C. A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer research. 2004;64(3):895-903.
Muller M, Demeret C. The HPV E2-Host Protein-Protein Interactions: A Complex Hijacking of the Cellular Network. The open virology journal. 2012;6:173-89.
Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC infectious diseases. 2014;14:87.
Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Reviews in obstetrics & gynecology. 2008;1(1):2-10.
de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. The Lancet Infectious diseases. 2007;7(7):453-9.
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Journal of clinical pathology. 2002;55(4):244-65.
Szostek S, Klimek M, Zawilinska B, Rys J, Kope J, Daszkiewic E. Detection of human papillomavirus in cervical cell specimens by hybrid capture and PCR with different primers. Acta biochimica Polonica. 2006;53(3):603-7.
Grahovac M, Racic I, Hadzisejdic I, Doric A, Grahovac B. Prevalence of human papillomavirus among Croatian women attending regular gynecological visit. Collegium antropologicum. 2007;31 Suppl 2:73-7.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. The New England journal of medicine. 2003;348(6):518-27.
Franceschi S, Clifford G, Plummer M. Prospects for primary prevention of cervical cancer in developing countries. Salud publica de Mexico. 2003;45 Suppl 3:S430-6.
Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. Human papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organization. 2007;85(9):719-26.
De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. International journal of cancer Journal international du cancer. 2009;124(7):1626-36.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International journal of cancer Journal international du cancer. 2007;121(3):621-32.
Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270-80.
Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecologic oncology. 2002;84(2):263-70.
Madeleine MM, Daling JR, Carter JJ, Wipf GC, Schwartz SM, McKnight B, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. Journal of the National Cancer Institute. 1997 ; 98 ( 02 :) 5151 - 02 .
Hildesheim A, Han CL, Brinton LA, Kurman RJ, Schiller JT. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstetrics and gynecology. 1997;90(5):74 - .15 9
Madsen BS, Jensen HL, van den Brule AJ, Wohlfahrt J, Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina--population-based case-control study in Denmark. International journal of cancer Journal international du cancer. 2008;122(12):2827-34.
Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Ellis N, et al. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2000;163(6):701-7.
Bhatla N, Moda N. The clinical utility of HPV DNA testing in cervical cancer screening strategies. The Indian journal of medical research. 2009;130(3):261-5.
Dempsey AF. Human papillomavirus: the usefulness of risk factors in determining who should get vaccinated. Reviews in obstetrics & gynecology. 2008;1(3):122-8.
Natphopsuk S, Settheetham-Ishida W, Sinawat S, Pientong C, Yuenyao P, Ishida T. Risk factors for cervical cancer in northeastern Thailand: detailed analyses of sexual and smoking behavior. Asian Pacific journal of cancer prevention : APJCP. 2012;13(11):548 - .81 829. Chichareon S, Herrero R, Munoz N, Bosch FX, Jacobs MV, Deacon J, et al. Risk factors for cervical cancer in Thailand: a case-control study. Journal of the National Cancer Institute. 1998;90(1):50-7.
Sellors JW, Mahony JB, Kaczorowski J, Lytwyn A, Bangura H, Chong S, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2000;163(5):503-8.
Jamal A, Al-Maghrabi JA. Profile of Pap smear cytology in the Western region of Saudi Arabia. Saudi medical journal. 2003;24(11):1225-9.
Tarkowski TA, Koumans EH, Sawyer M, Pierce A, Black CM, Papp JR, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. The Journal of infectious diseases. 2004;189(1):46-50.
Altuglu I, Terek MC, Ozacar T, Ozsaran AA, Bilgic A. The prevalence of human papilloma virus DNA in women with mucopurulent endocervicitis. European journal of gynaecological oncology. 2002;23(2):166-8.
Valdespino Gomez VM, Valdespino Castillo VE. (Current perspectives in cervical cancer). Ginecologia y obstetricia de Mexico. 2004;72(1):29-38.
Barghi MR, Hajimohammadmehdiarbab A, Moghaddam SM, Kazemi B. Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC infectious diseases. 2005;5:102.
Farjadian S, Asadi E, Doroudchi M, Dehaghani AS, Tabei SZ, Kumar VP, et al. High risk HPV types in southern Iranian patients with cervical cancer. Pathology oncology research : POR. 2003;9(2):121-5.
- Abstract Viewed: 440 times
- PDF Downloaded: 302 times